MITO INJECTION is an antineoplastic cytotoxic antibiotic. Mitomycin acts as an alkylating agent with potent antitumor activity.
Mechanism of action:
After intracellular activation, mitomycin forms cross-links in DNA, disrupting replication and transcription processes. This inhibits tumor cell division and induces cell death. It is particularly active against rapidly proliferating cancer cells.
Recommended for:
Clinical evidence:
Mitomycin has been used in oncology for decades and is included in multiple combination chemotherapy regimens. Clinical studies have confirmed its efficacy in gastric and pancreatic cancers and in superficial bladder cancer when administered intravesically. It has demonstrated the ability to reduce recurrence risk in adjuvant urological therapy.
Indicated for the treatment of various malignant tumors, including gastric, pancreatic, and bladder cancers, as well as other solid malignancies. Works by inhibiting DNA synthesis and blocking tumor cell proliferation.
Administered intravenously or intravesically under strict medical supervision. Dosage and treatment schedule are determined individually based on tumor type, stage, and patient condition. Therapy is given in cycles with regular blood count monitoring.
Contraindications
Side Effects
